抗体来源(Source)
HRP conjugated Monoclonal Anti-DM-1&DM-4 Antibody,Mouse IgG1 antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with DM-1.
亚型(Isotype)
Mouse IgG1/kappa
特异性(Specificity)
This product is a specific antibody specifically reacts with DM-1.
应用(Application)
ELISA
纯度(Purity)
>90% as determined by SDS-PAGE.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳(SDS-PAGE)
HRP conjugated Monoclonal Anti-DM-1&DM-4 Antibody,Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
活性(Bioactivity)-ELISA
Immobilized Trastuzumab-DM1 (T-DM1) at 2 μg/mL (100 μL/well) can bind HRP conjugated Monoclonal Anti-DM-1&DM-4 Antibody,Mouse IgG1 (Cat. No. DM1-PLY73) with a linear range of 0.24-15.63 ng/mL (QC tested).
Protocol
背景(Background)
Mertansine (DM-1) is a tubulin inhibitor that binds to the ends of microtubules and inhibits microtubule dynamics. DM-1(Mertansine) has antitumor activity and functions as a regulator of tubulin. It is an alpha-amino acid ester, a carbamate, an epoxide, an organic heterocyclic tetracyclic compound, an organochlorine compound, a mercaptan, and a maydenin alkaloid. DM-1, derived from Mydenin, is a cytotoxic component of antibody-drug conjugations that produce antibody-drug conjugations via a sulfhydryl group splice with SPP (n-succinimide 4- (2-pyridyl dithio)) or SMCC (4- (3-mercapto-2, 5-dioxy-1 pyrrolidyl) -cyclohexanic acid) splice.